IDH2 and acute myeloid leukemia: IDH inhibitors as monotherapy or combined with other chemotherapy have shown impressive activity in IDH-mutated AML, both in the upfront and relapsed/refractory setting [44]; reported overall (ORR) and complete (CR) response rates with ivosidenib [45] or enasidenib [46] monotherapy were approximately 40% and 20%, respectively, and in combination with chemotherapy ranged from 63 t% to 89% for ORR and 47% to 68% for CR [44].